title: Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
abstract: We evaluated and compared patients' long-term adherence to biological therapies in a real-life clinical setting. Secondary aims included weight changes on biological therapy and reporting adverse effects. This prospective case-note review included 58 patients, undergoing 84 treatment series including etanercept (21), adalimumab (24), infliximab (14) and ustekinumab (25). Patients' adherence was greatest with ustekinumab (being 6.7-fold less likely to withdraw from treatment than etanercept, P = 0.014), while the difference in treatment adherence of adalimumab and infliximab compared to etanercept was not statistically significant. Adalimumab and infliximab were associated with an increase in weight, while ustekinumab was associated with weight loss compared with etanercept (not statistically significant). Long-term patient adherence to biologic therapy in patients with psoriasis is greatest with ustekinumab.
authors.affiliation: Department of Dermatology, Flinders Medical Centre, Bedford Park, South Australia, Australia.
authors.forename: Christopher
authors.initials: C
authors.lastname: Ross
authors.affiliation: Department of Dermatology, Flinders Medical Centre, Bedford Park, South Australia, Australia.
authors.forename: Gillian
authors.initials: G
authors.lastname: Marshman
authors.affiliation: Department of Dermatology, Flinders Medical Centre, Bedford Park, South Australia, Australia.
authors.forename: Marianne
authors.initials: M
authors.lastname: Grillo
authors.affiliation: Discipline of Statistics, School of Mathematics, University of Adelaide, Adelaide, South Australia, Australia.
authors.forename: Tyman
authors.initials: T
authors.lastname: Stanford
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068800:Etanercept / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D000069549:Ustekinumab / Q000627:therapeutic use
chemical_list: D001688:Biological Products; D003879:Dermatologic Agents; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept
keywords: PASI; adalimumab; anti-TNF-α; biologics; drug survival; etanercept; infliximab; psoriasis; ustekinumab